Medistep HealthcareNSE:MEDISTEP -5.24%19 EBITDA Margin % is 11.28% as of Mar. 2025, which is 37% above its 10-year median of 8.23. GuruFocus rates NSE:MEDISTEP with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Medistep Healthcare ranks better than 77.78% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medistep Healthcare EBITDA Margin % Related Terms
Medistep Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medistep Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistep Healthcare EBITDA Margin % Chart
Medistep Healthcare Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
EBITDA Margin %
4.69
5.17
11.65
11.28
Medistep Healthcare Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
EBITDA Margin %
4.69
5.17
11.65
11.28
NSE:MEDISTEP vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Medistep Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistep Healthcare EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medistep Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medistep Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistep Healthcare (NSE:MEDISTEP) has a EBITDA Margin % of 11.28% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medistep Healthcare and its competitors. This is 37% above median its historical median of 8.23. Over the past decade, Medistep Healthcare's EBITDA Margin % has ranged from 4.69 to 11.65. According to the industry distribution chart, Medistep Healthcare ranks #26 out of 117 companies in the Medical Distribution industry, placing it in the top 22.2%.
Is Medistep Healthcare's EBITDA Margin % too high?
Medistep Healthcare's current EBITDA Margin % of 11.28% is 37% above median its 10-year median of 8.23. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 11.65. The Medical Distribution industry median EBITDA Margin % is 4.28. Medistep Healthcare's value of 11.28% is 163.6% above this industry median. Based on the distribution chart, Medistep Healthcare ranks #26 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Medistep Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medistep Healthcare's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medistep Healthcare ranks #26 out of 117 companies for EBITDA Margin %. This places Medistep Healthcare in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.28. Medistep Healthcare's value of 11.28% is 163.6% above this benchmark. Historically, Medistep Healthcare's own EBITDA Margin % has ranged from 4.69 to 11.65 over the past decade. While the company's 10-year median is 8.23 vs. the industry median of 4.28, Medistep Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistep Healthcare's current EBITDA Margin % of 11.28% is 163.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medistep Healthcare and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistep Healthcare's current EBITDA Margin % is 11.28%, which is 37% above median its own 10-year median of 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistep Healthcare stock overvalued right now?
Medistep Healthcare (NSE:MEDISTEP) has a current EBITDA Margin % of 11.28%. The current EBITDA Margin % is 11.28%, which is 37% above median its 10-year median of 8.23 and 163.6% above the Medical Distribution industry median of 4.28. Medistep Healthcare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medistep Healthcare (NSE:MEDISTEP), the current EBITDA Margin % is 11.28% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medistep Healthcare Ltd operates in the pharmaceutical and healthcare product sectors. Its business includes manufacturing intimate care and hygiene products such as sanitary pads, as well as nutraceutical products like energy powders. The company also trades a variety of pharmaceutical, surgical, and medical equipment products. Medistep Healthcare's operations focus mainly on the western region of India, particularly in Gujarat. Its Core business activity is divided into the following categories: a) Trading of Pharmaceutical & Surgical products, b) Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products. The company generates the majority of its revenue from Trading and distribution.
19GF Score
Get the complete analysis for NSE:MEDISTEP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDISTEP has been successfully added to your 